Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04274114
Other study ID # PS18-00018
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date January 18, 2019
Est. completion date May 12, 2020

Study information

Verified date February 2021
Source Hospital Universitario Dr. Jose E. Gonzalez
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this randomized clinical trial is to examine the efficacy of L-glutamine for the treatment of generalized anxiety disorder compared versus placebo.


Recruitment information / eligibility

Status Terminated
Enrollment 38
Est. completion date May 12, 2020
Est. primary completion date May 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Outpatients with generalized anxiety disorder defined by the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) - Generalized anxiety disorder is the primary psychiatric disorder. - Untreated patients or; patients treated with paroxetine, sertraline, citalopram, escitalopram, venlafaxine or duloxetine at least for 6 weeks on a stable dose; or patients treated with any benzodiazepine at least for 4 weeks on a stable dose. - Hamilton Anxiety Rating Scale score major or equal to 20 and a score major or equal to 2 on items 1 and 2 of the same scale at both screening and baseline. - Clinical Global Impression-Severity major or equal to 4 at both screening and baseline. Exclusion Criteria: - Unable to give informed consent. - Currently participating in another clinical research. - Any other psychiatric disorder not included in the Anxiety Disorders section of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Secondary diagnosis of other anxiety disorders are allowed provided the diagnosis is not more prominent than generalized anxiety disorder symptoms. - Suicide risk as assessed by the researcher at screening or baseline. - History of substance abuse in the previous six months before the screening visit. - Suffering a medically relevant or instable disease. - If woman, being pregnant at screening visit. - If woman, being breastfeeding. - A score major or equal to 20 on the Montgomery-Asberg Depression Rating Scale at screening or baseline. - As judged by a researcher, the patient might not adhere to the intervention or complete follow-up. - History of use of a banned drug in the past two weeks prior the baseline visit; three weeks in the case of monoamine oxidase inhibitors; one week in the case of fluvoxamine or a tricyclic antidepressant; two weeks for any antipsychotic and; six weeks por long-acting injectable antipsychotics. - History of use of L-glutamine the most part of the days of the previous month before the baseline visit. - History of psychotherapy treatment in the past month before the baseline visit.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
L Glutamine
Powder
Placebos
Powder

Locations

Country Name City State
Mexico Hospital Universitario Dr. Jose E. Gonzalez Monterrey Nuevo León

Sponsors (2)

Lead Sponsor Collaborator
Hospital Universitario Dr. Jose E. Gonzalez Instituto de Información e Investigación en Salud Mental A. C.

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response on Clinical Global Impression-Improvement Score of 1 or 2 Change from baseline to week 8
Secondary Response on Hamilton Anxiety Rating Scale Reduction of baseline score major or equal to 50 % Change from baseline to week 8
Secondary Reduction of Hamilton Anxiety Rating Scale score Difference between baseline and final score Change from baseline to week 8
See also
  Status Clinical Trial Phase
Terminated NCT03420456 - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Withdrawn NCT02382224 - Worry Exposure for Generalized Anxiety Disorder N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT02306356 - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting N/A
Completed NCT01958788 - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder N/A
Completed NCT01681329 - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder N/A
Completed NCT01337713 - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD) N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT01342120 - PHARMO Institute Seroquel Safety Study N/A
Completed NCT01203293 - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector Phase 1
Completed NCT01971203 - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat N/A
Completed NCT00961298 - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Phase 4
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00744627 - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Phase 3
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00537615 - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers Phase 1
Completed NCT00515242 - Therapeutic Massage for Generalized Anxiety Disorder Phase 1/Phase 2
Completed NCT00368745 - Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. Phase 3